AG-636 217903 Smiles: CC(=O)O[C@]12[C@H]3[C@@H](OC(=O)C4C=CC=CC=4)[C@](O)(C[C@H]3C34[C@@H]5[C@@H](OC)C1C3N(C[C@@]5(CC[C@@H]4OC)COC)CC)[C@@H](OC)[C@@H]2O

Smiles: CC(=O)O[C@]12[C@H]3[C@@H](OC(=O)C4C=CC=CC=4)[C@](O)(C[C@H]3C34[C@@H]5[C@@H](OC)C1C3N(C[C@@]5(CC[C@@H]4OC)COC)CC)[C@@H](OC)[C@@H]2O

5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3-iodo-5

9 μM are obtained after 1 day of treatment with Reserpine hydrochloride in JB6 P+ and HepG2-C8 cells

absorption=546

AG-636 217903 Smiles: CC(=O)O[C@]12[C@H]3[C@@H](OC(=O)C4C=CC=CC=4)[C@](O)(C[C@H]3C34[C@@H]5[C@@H](OC)C1C3N(C[C@@]5(CC[C@@H]4OC)COC)CC)[C@@H](OC)[C@@H]2OAG 636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. Differential AG 636 activity translated to the in vivo setting, with complete tumor regression observed in a lymphoma model. Dissection of the relationship between uridine availability and response to AG 636 revealed a divergent ability of lymphoma and solid tumor cell lines to survive and grow in the setting of depleted